Anthropometric characteristics at birth and growth outcome in patients with X-linked hypophosphatemia treated with oral phosphate and active vitamin D

Read full text
Authors: Stephan Przygodda, Laura Celine Brieger, Alina Verena Bohlen, Mirko Rehberg, Martin Konrad, Karl Peter Schlingmann, Olaf Hiort, Dorothée Schmidt, Ulrike John-Kroegel, Elke Wühl, Markus Josef Kemper, Ute Derichs
+34 more Ludwig Patzer, Norbert Albers, Désirée Dunstheimer, Sabine Heger, Karina Grohmann-Held, Carmen Schroeder, Norbert Jorch, Elmar Schmid, Hagen Staude, Marcus Weitz, Lena Lecher, Clemens Freiberg, Angela Huebner, Anke Heitmeyer-Pyper, Giuseppina Spartà, Katrina Suzanne Evers, Anne Juliane Ostendorf, C. J. Partsch, Michaela Marx, Christof Land, Inka Baus, Frauke Wilkening, Kristina Moeller, Gunter Ŝimić-Schleicher, Susann Empting, Dominik Müller, Oliver Metzing, Verena Wagner, Martin Holder, Mislav Stjepan Žebec, Dirk Schnabel, Dieter Haffner, Miroslav Živičnjak, On behalf of the German Society for Pediatric Nephrology (GPN), the German Society for Pediatric, Adolescent Endocrinology, Diabetology (DGPAED)
Cited by: 1
References: 43

Abstract

BACKGROUND: X-linked hypophosphatemia (XLH) is the most common form of inherited rickets, resulting in short stature despite treatment with oral phosphate and active vitamin D. Detailed data of anthropometric parameters at birth, during infancy, and on the influence of an affected parent on outcome are lacking. METHODS: In this prospective multicenter observational study, conducted from 1998 to 2023 in Germany, Austria, and Switzerland, body length, body weight, and head circumference were investigated in 198 children with XLH from birth until the age of 18 years, all being only on supplementation therapy. RESULTS: XLH newborns presented with disproportionate body shape characterized by decreased birth length relative to weight and head circumference with a 2.4-fold increased risk to be born small for gestational age (SGA). A positive family history for XLH was associated with lower anthropometric characteristics at birth. Body disproportion increased during 0-2 years old, resulting in significantly increased head circumference (+ 0.82 SD) and reduced body length (-2.00 SD) compared to healthy 2-year-old patients. Supplementation therapy failed to prevent progressive growth failure and reduced final height, regardless of whether treatment was started early due to an affected family member, which was associated with overall poor control of metabolic bone disease indicated by persistent hypophosphatemia and rising alkaline phosphatase z-score. CONCLUSIONS: XLH is associated with an increased risk for SGA and progressive disproportional body growth during infancy. Routine medical check-ups may soon use this unique growth pattern to identify children with XLH. Supplemental therapy fails to prevent progressive growth failure.

Fields of Study & Subjects

Parathyroid Disorders and Treatments Alkaline Phosphatase Research Studies Bone health and osteoporosis research

Publication details

Journal / source
Pediatric Nephrology
Publisher
Springer Science and Business Media LLC
Volume
41
Issue
9
Pages
3033–3046
Publication date
10 April 2026
Language
EN